Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants
Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2009, 8: 87-92. PMID: 19270153, DOI: 10.1177/1545109709332471.Peer-Reviewed Original ResearchConceptsMean CD4 count increaseCD4 count increaseCombination of raltegravirTreatment-experienced patientsPotent antiretroviral activityCopies/mLProtease inhibitorsARV agentsUnboosted atazanavirHIV RNAImmunologic outcomesTwice DailyAntiretroviral treatmentARV therapyAntiretroviral agentsCase seriesHIV integrase inhibitorsTherapeutic failureAntiretroviral activityRaltegravirAtazanavirIntegrase inhibitorsAdverse effectsCells/Count increase